Strategic Focus Target spinal cord injury treatment providers and neuroscience research centers that may benefit from biocompatible scaffolds and MTA therapies. Leverage INSPIRE pivotal study data and HUD designation to position as a cutting-edge implantable biomaterial solution for acute SCI care.

Clinical Milestones Highlight progress and publications from INSPIRE studies, including 12- and 24-month data, to demonstrate safety signals and potential efficacy. Use milestone-driven narratives to engage surgeons, hospital procurement, and academic partners pursuing innovative SCI interventions.

Strategic Partnerships Explore collaborations with CNS cell therapy companies (e.g., Q Therapeutics) and academic medical centers for combined regenerative approaches. Joint ventures could expand the addressable market in acute SCI and enhance trial feasibility.

Regulatory & Funding Emphasize HUD designation status and humanitarian use case to support discussions with payers and hospitals on access pathways. Leverage existing funding and growth narrative to attract investors and potential co-funding for expansion.

Operational Signals Acknowledge recent leadership appointments and bankruptcy filing as potential risk signals; frame discussions around stability, ongoing clinical programs, and plans to de-risk procurement and supply chains for hospital adoption.